Trinity Biotech conducts strategic portfolio review

The company said, "The Company is conducting a portfolio review of all activities that do not align with its strategic focus around three key priorities, specifically: Diabetes/Haemoglobins; Point of Care & Digital Health Disruption; Personalized Therapeutic Drug Monitoring.Management intends to exit or optimize for cash its portfolio of non-core products and platforms in order to maximise shareholder value. Given the strong pipeline of attractive M&A opportunities in our areas of strategic focus, in February 2023 the Company secured a $20 million flexible term-facility specifically to provide the ability to move quickly when opportunistic transactions arise.Our portfolio optimization efforts and opportunistic M&A are key to our efforts to optimize our capital structure and reduce our debt costs in 2023."